SELLAS Life Sciences Group (SLS) Earnings Analysis

SELLAS Life Sciences Group (SLS) next reports earnings on 2026-08-11, consensus EPS -0.045 USD. Last quarter (2026-03-19) it beat with EPS -0.05 USD vs -0.06333 USD est (+21%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E -52.91.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does SLS next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.045 USD
Revenue estimaten/a

SLS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-19-0.05 USD-0.06333 USD+21%Beat
2025-11-12-0.06 USD-0.06333 USD+5.3%Beat
2025-03-20-0.08 USD-0.11 USD+27.3%Beat

Beat rate: 3/3 (100%) over reported quarters with consensus data.

SLS valuation and analyst view

Trailing P/E-52.91
Trailing EPS-0.17078 USD
Price / book19.40
Dividend yield0.00%
Market cap2.24B
Analyst consensusBuy (5 buy / 0 hold / 0 sell)
Avg price target25 USD

Related research pages

Frequently asked questions

When is SELLAS Life Sciences Group (SLS)'s next earnings date?

SELLAS Life Sciences Group is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.045 USD.

Did SLS beat earnings last quarter?

In its 2026-03-19 report, SLS posted EPS of -0.05 USD versus a -0.06333 USD estimate — a beat of 21%.

What is SLS's earnings track record?

Over the last 3 reported quarters with consensus data, SLS beat estimates 3 times (100%).

What is SLS's current P/E ratio and EPS?

SLS trades at a trailing P/E of -52.91 on trailing EPS of -0.17078349271009818 USD.

What do analysts rate SLS?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 25 USD.